"Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients" by John M. Pagel

Selected Works of John M. Pagel, MD, PhD

Follow Contact

Article

Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients

British Journal of Haematology (2015)

John M. Pagel, University of Washington
Stephen E. Spurgeon, Oregon Health & Science University
John C. Byrd, Ohio State University
Farrukh T. Awan, Ohio State University
Ian W. Flinn, Sarah Cannon Research Institute
Mark C. Lanasa, Duke University
Amy J. Eisenfeld
Scott C. Stromatt
Ajay K. Gopal, University of Washington

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

January 1, 2015

DOI

10.1111/bjh.13099

Citation Information

John M. Pagel, Stephen E. Spurgeon, John C. Byrd, Farrukh T. Awan, et al.. "Otlertuzumab (TRU‐016), an anti‐CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients" British Journal of Haematology Vol. 168 Iss. 1 (2015) p. 38 - 45
Available at: http://works.bepress.com/john-pagel/81/